Jefferies Financial Group Inc. Takes $8.27 Million Position in GH Research PLC (NASDAQ:GHRS)

Key Points

• Jefferies Financial Group Inc. has invested approximately $8.27 million in GH Research PLC, acquiring 750,000 shares and representing about 1.44% of the company's total stock.
• GH Research reported an earnings per share (EPS) of (-$0.19) for the last quarter, which was better than analysts' expectations of (-$0.61).
• Several analysts have given GH Research a consensus target price of $32.00, with most rating it a "Moderate Buy," indicating a bullish outlook for the stock.

Jefferies Financial Group Inc. acquired a new position in shares of GH Research PLC (NASDAQ:GHRS - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 750,000 shares of the company's stock, valued at approximately $8,272,000. Jefferies Financial Group Inc. owned approximately 1.44% of GH Research as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of GHRS. BNP Paribas Financial Markets bought a new position in shares of GH Research during the fourth quarter valued at about $44,000. Two Sigma Investments LP purchased a new stake in GH Research during the 4th quarter valued at $117,000. Palumbo Wealth Management LLC bought a new stake in shares of GH Research during the 1st quarter valued at $142,000. Millennium Management LLC bought a new position in GH Research in the 4th quarter worth $145,000. Finally, XTX Topco Ltd purchased a new stake in GH Research in the 1st quarter worth $169,000. 56.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GHRS has been the topic of a number of research analyst reports. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of GH Research in a research note on Friday, May 9th. Guggenheim decreased their target price on shares of GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a research report on Friday, May 9th. JMP Securities reissued a "market outperform" rating and set a $39.00 target price on shares of GH Research in a research report on Tuesday, June 24th. Cantor Fitzgerald assumed coverage on shares of GH Research in a report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 price target for the company. Finally, Wall Street Zen raised shares of GH Research from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.

GH Research Price Performance

GHRS stock traded down $0.90 during midday trading on Wednesday, hitting $12.16. 324,621 shares of the stock traded hands, compared to its average volume of 341,613. The firm has a market cap of $632.68 million, a P/E ratio of -15.34 and a beta of 0.98. The stock's fifty day simple moving average is $13.89 and its 200-day simple moving average is $11.99. GH Research PLC has a 1-year low of $6.00 and a 1-year high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.42. On average, research analysts predict that GH Research PLC will post -0.8 earnings per share for the current year.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).